- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.
Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.
Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.
Latest from The University of Texas MD Anderson Cancer Center
Five Under 5: Top Oncology Videos for the Week of 12/7
December 14, 2025
Article
The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.
Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML
December 10, 2025
Video
Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.
Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML
December 09, 2025
Video
Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.
Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma
December 08, 2025
Video
Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.
Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis
December 07, 2025
Article
Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.
Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL
December 07, 2025
Video
Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.
Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML
December 07, 2025
Video
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.
Experts Prepare for Several Key MCL Presentations at ASH 2025
December 05, 2025
Article
Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.
OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know
December 02, 2025
Article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.
Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS
December 02, 2025
Podcast
Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.
CPRIT Awards MD Anderson Over $29 million for Prevention Efforts, Cancer Research, and Faculty Recruitment
November 24, 2025
Article
MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.
MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting
November 11, 2025
Article
Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.
Comprehensive Molecular Profiling of Renal Medullary Carcinoma Identifies TROP2 As a Promising Therapeutic Target
November 06, 2025
Article
Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.
CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC
November 05, 2025
Article
A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.
OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know
October 31, 2025
Article
Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.
Allison Institute’s Third Annual Scientific Symposium Highlighted By Panel Discussion With Five Nobel Laureates
October 30, 2025
Article
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.
Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025
October 30, 2025
Article
Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.
FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD
October 27, 2025
Podcast
Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.
Five Under 5: Top Oncology Videos for the Week of 10/19
October 26, 2025
Article
The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.
Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC
October 24, 2025
Article
Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.